AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02719912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mitral valve replacement
Description: transcatheter mitral valve replacement
Study NCT02284659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation (FES)
Description: FES (50Hz / 500us)
Study NCT02284659 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FES- Sham
Study NCT02925715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided central venous cannulation
Description: ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
Study NCT03149263 — intervention group
Intervention type: BEHAVIORAL
Intervention: distraction
Description: Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
Study NCT00315913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
Study NCT00315913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV Saline Solution
Study NCT01382940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1000 mg in 250 mL intravenous infusion
Study NCT01382940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10 to 25 mg/week (oral or parenteral)
Study NCT01382940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
Study NCT01382940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
Study NCT01382940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: 50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
Study NCT01493661 — intervention group
Intervention type: OTHER
Intervention: Chronic Sleep Restriction
Description: All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
Study NCT04014478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Denervation
Description: A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
Study NCT00836173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RICE
Description: RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
Study NCT00836173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GaRD Treatment
Description: After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
Study NCT01752595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preference Based Rhythmic Auditory Stimulation Music
Description: Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most.
Study NCT01752595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preference Based Music Intervention
Study NCT03273140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamification Diabetes Education Program (GDEP)
Description: Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform.
Study NCT00329017 — intervention group
Intervention type: PROCEDURE
Intervention: Fine needle aspiration
Description: Fine needle aspiration
Study NCT02936492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803 0.01% lipophilic cream
Description: Topical administration for 22 h per day
Study NCT02936492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803 0.1% lipophilic cream
Description: Topical administration for 22 h per day
Study NCT02936492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803 0.01% ointment
Description: Topical administration for 22 h per day
Study NCT02936492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803 0.1% ointment
Description: Topical administration for 22 h per day
Study NCT02936492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipophilic cream vehicle
Description: Topical administration for 22 h per day
Study NCT02936492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ointment vehicle
Description: Topical administration for 22 h per day
Study NCT01097395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
Study NCT01097395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
Study NCT03621722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elequil Aromatabs
Description: There will be a variety of different Aromatabs such as orange/peppermint or lavender
Study NCT04896944 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02609659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Study NCT02609659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet
Study NCT02936492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate
Description: Topical administration for 22 h per day
Study NCT01176136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homework, Organization, and Planning Skills (HOPS) Intervention
Description: HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
Study NCT00924599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)
Description: Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
Study NCT02757521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: 50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Study NCT02757521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Study NCT04258085 — intervention group
Intervention type: OTHER
Intervention: Early diagnosis program combined with electronic medical record
Description: Implementation of early diagnosis approach targeting symptomatic women, combined with use of electronic medical record to facilitate documentation, patient tracking across levels of the health care system, and patient contact
Study NCT01562002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell with Amniotic Membrane Transplant
Description: Single stem cell expansion in amniotic membrane transplant
Study NCT01562002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell with Amniotic Membrane Transplant
Description: Single stem cell expansion in amniotic membrane transplant
Study NCT03753282 — intervention group
Intervention type: OTHER
Intervention: questionnaires for patient reported outcome
Description: questionnaires with respect to outcomes:~* Reoperations~* Short term complications~* Long term complications~* EQ-5D (current)~* HOOS (current)~* disease related change of occupation~* use of walking aids~* comorbidities~* medication
Study NCT03753282 — intervention group
Intervention type: OTHER
Intervention: questionnaire for course of the disease
Description: questionnaires to assess course of the disease:~* from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~* therapeutic interventions
Study NCT05051332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Chondrocyte Implantation (CartiLife®)
Description: CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
Study NCT05051332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture Surgery
Description: Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate
Study NCT04291235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Management Pathway
Description: Patients in this group will receive several components that comprise airway management pathway: (1) daily spontaneous breathing trials (SBTs); (2) prompt extubation following successful extubation readiness criteria; (3) high-flow nasal oxygen for at least 24 hours following extubation.
Study NCT04291235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in this group will be treated according to usual care, which may include extubation or tracheostomy timed according to treating physicians' discretion.
Study NCT01061437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACx14
Description: Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
Study NCT01061437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACMx5
Description: Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
Study NCT01061437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAx5/PCMx5
Description: Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
Study NCT02767635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox-Epic
Description: injected 20 units of Botox into lateral epicondyle in Botox-Epic group
Study NCT02767635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox-Tend
Description: injected 20 units of Botox into tender point of muscles in Botox-Tend group
Study NCT02767635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide (Steroid)
Description: injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
Study NCT02991235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRJ212
Description: 6 capsules of study product will be taken daily and orally.
Study NCT02991235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules of study product will be taken daily and orally.
Study NCT01024647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: certolizumab pegol
Description: certolizumab pegol 200 mg every 2 weeks
Study NCT01024647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: certolizumab pegol
Description: certolizumab pegol 400 mg every 2 weeks
Study NCT01024647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: certolizumab pegol
Description: certolizumab pegol 400 mg every 4 weeks
Study NCT03636360 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light
Description: 15 hours of light exposure
Study NCT03636360 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light
Description: 15 hours of light exposure
Study NCT03636360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light
Description: 15 hours of light exposure
Study NCT00451217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered
Study NCT00451217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
Study NCT00953914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
Study NCT00953914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
Study NCT00924599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle education (English & Spanish)
Description: The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
Study NCT00984139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Intramuscular, one dose.
Study NCT02715700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
Study NCT02715700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg oral tablet once per day.
Study NCT02062424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIPI
Study NCT02780024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin,
Study NCT00538044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
Study NCT01950273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500
Description: BI695500, once a week for 4 weeks (4 administrations in total)
Study NCT06394856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair With a Modified Versus Classic Double-Row Suture -Bridge Techniques
Description: rotator cuff tears with modified versus classic double row suture bridge
Study NCT00258349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00258349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT03499691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 500 medium cut-off dialyzer
Description: The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
Study NCT03499691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
Study NCT02224027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: proceal laryngeal mask airway
Description: In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
Study NCT02224027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tracheal tube
Description: In tracheal tube group, tracheal tube is intubated by novices.
Study NCT02224027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: In i-gel group, i-gel is inserted by novices.
Study NCT03940274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking training
Description: Participants will receive three sessions a week of BWSTT with assistive training device for 8 weeks; a total of 24 sessions. The duration of each training session will an hour. During walk-training, the participant will wear a harness which is attached to an overhead motorized lift to provide body-weight support and to prevent the risk of falling.
Study NCT02085668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation (Symplicity™)
Description: Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
Study NCT01892709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Study NCT02210286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magtein
Study NCT00559780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks of resistance training (3/week)
Study NCT00559780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of the quadriceps muscle
Description: 12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
Study NCT00559780 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard rehabilitation
Description: 12 weeks of standard physiotherapy exercises (1h/day)
Study NCT00774527 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Cyclophosphamide-fludarabine-anti thymocyte globulin
Description: * Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~* Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~* Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.
Study NCT02395237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: : Amaryl® M IR 2/1000